Seawolf Raises $100M, Signs Potential $1.2B Sanofi Pact
San Diego biotech Seawolf Therapeutics has emerged from stealth with $100 million in seed and Series A financing led by founding investor Versant Ventures and backed by investors including Eli Lilly, Novartis, CRISPR Therapeutics and MPM BioImpact. The company is developing its Trident platform, which uses lipid nanoparticles to deliver DNA designed for repeat dosing, and says its lead program targets metabolic diseases. Seawolf also announced a multi-target research and exclusive licensing agreement with Sanofi to develop treatments for bleeding disorders and other undisclosed conditions; the deal could bring Seawolf up to $1.2 billion in milestone payments, plus royalties on any resulting products.




